Synopsis: Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.
Structural formula:
Properties
Summary
Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.
Manufacturing
